These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17220808)

  • 41. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor.
    Durrbach A; Rostaing L; Tricot L; Ouali N; Wolf P; Pouteil-Noble C; Kessler M; Viron B; Thervet E
    Transplantation; 2008 Feb; 85(3):486-90. PubMed ID: 18301342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of variability of sirolimus trough level on chronic allograft nephropathy.
    Wu MJ; Shu KH; Lian JD; Yang CR; Cheng CH; Chen CH
    Transplant Proc; 2008 Sep; 40(7):2202-5. PubMed ID: 18790192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation.
    Jabs A; Göbel S; Wenzel P; Kleschyov AL; Hortmann M; Oelze M; Daiber A; Münzel T
    J Am Coll Cardiol; 2008 Jun; 51(22):2130-8. PubMed ID: 18510959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Actin cytoskeletal and functional studies of the proximal convoluted tubules after preservation.
    Figueiredo JF; Bertels IM; Gontijo JA
    Transplant Proc; 2008 Dec; 40(10):3311-5. PubMed ID: 19100379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sirolimus: a new immunosuppressant.
    Mukherjee T; Shah BV
    J Assoc Physicians India; 2005 Oct; 53():885-90. PubMed ID: 16459533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
    Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria.
    Ruiz JC; Campistol JM; Sanchez-Fructuoso A; Mota A; Grinyo JM; Paul J; Castro-Henriques A; Reimao-Pinto J; Garcia J; Morales JM; Granados E; Arias M
    Transplant Proc; 2007 Sep; 39(7):2151-2. PubMed ID: 17889121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteinuria in transplant patients associated with sirolimus.
    Franco AF; Martini D; Abensur H; Noronha IL
    Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endocytosis.
    Mallet WG; Maxfield FR
    Adv Nephrol Necker Hosp; 2000; 30():109-25. PubMed ID: 11068638
    [No Abstract]   [Full Text] [Related]  

  • 50. The impact of sirolimus on sex hormones in male adolescent kidney recipients.
    González D; Álvarez-García O; Santos F
    Pediatr Transplant; 2012 Jun; 16(4):310-1. PubMed ID: 22471728
    [No Abstract]   [Full Text] [Related]  

  • 51. Chronic hypophosphatemia in the renal homograft recipient.
    Takagi H; Uchida K; Tominaga Y; Yamada N; Ishii T; Morimoto T; Yasue M
    Nagoya J Med Sci; 1982 Mar; 44(3-4):83-7. PubMed ID: 7050723
    [No Abstract]   [Full Text] [Related]  

  • 52. "Nomen not est omen": the (pro)renin receptor and receptor-mediated endocytosis in the proximal tubule-a new (pro)renin-independent role forATP6ap2.
    Peters J
    Pflugers Arch; 2021 Aug; 473(8):1173-1174. PubMed ID: 34240240
    [No Abstract]   [Full Text] [Related]  

  • 53. Endocytosis in the proximal tubule.
    Carney EF
    Nat Rev Nephrol; 2019 Jan; 15(1):2. PubMed ID: 30367173
    [No Abstract]   [Full Text] [Related]  

  • 54. Sirolimus and growth.
    Santos F; Alvarez-García O; González D
    Pediatr Transplant; 2011 Sep; 15(6):546-7. PubMed ID: 21762331
    [No Abstract]   [Full Text] [Related]  

  • 55. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
    Torres VE; Boletta A; Chapman A; Gattone V; Pei Y; Qian Q; Wallace DP; Weimbs T; Wüthrich RP
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1312-29. PubMed ID: 20498248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells.
    Mreich E; Coombes JD; Rangan GK
    Transplantation; 2007 Jan; 83(1):105-7. PubMed ID: 17220808
    [No Abstract]   [Full Text] [Related]  

  • 57. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway.
    Oroszlán M; Bieri M; Ligeti N; Farkas A; Meier B; Marti HP; Mohacsi P
    Transpl Immunol; 2010 Jul; 23(3):125-32. PubMed ID: 20470887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney.
    Jouret F; Bernard A; Hermans C; Dom G; Terryn S; Leal T; Lebecque P; Cassiman JJ; Scholte BJ; de Jonge HR; Courtoy PJ; Devuyst O
    J Am Soc Nephrol; 2007 Mar; 18(3):707-18. PubMed ID: 17287432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of receptor mediated endocytosis in proximal tubule epithelial function.
    Linas SL
    Kidney Int Suppl; 1997 Oct; 61():S18-21. PubMed ID: 9328957
    [No Abstract]   [Full Text] [Related]  

  • 60. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells.
    Lebeau C; Arlt VM; Schmeiser HH; Boom A; Verroust PJ; Devuyst O; Beauwens R
    Kidney Int; 2001 Oct; 60(4):1332-42. PubMed ID: 11576347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.